Liau, Linda M.

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature

Glioma Diagnosis and TreatmentCancer, Hypoxia, and Metabolism

Cited by 4,154

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors

Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., Yoshimoto, K., Huang, J. H. Y., Chute, D. J., et al. (2005) · New England Journal of Medicine

Glioma Diagnosis and TreatmentHER2/EGFR in Cancer Research

Cited by 1,442

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

Cloughesy, T. F., Mochizuki, A. Y., Orpilla, J. R., Hugo, W., Lee, A. H., Davidson, T. B., Wang, A. C., Ellingson, B. M., Rytlewski, J. A., Sanders, C. M., et al. (2019) · Nature Medicine

Glioma Diagnosis and TreatmentCancer Immunotherapy and Biomarkers

Cited by 1,382

Intertumoral Heterogeneity within Medulloblastoma Subgroups

Cavalli, F. M. G., Remke, M., Rampasek, L., Peacock, J., Shih, D. J. H., Luu, B., Garzia, L., Torchia, J., Nor, C., Morrissy, A. S., et al. (2017) · Cancer Cell

Glioma Diagnosis and TreatmentCancer Genomics and Diagnostics

Cited by 1,219

The whole-genome landscape of medulloblastoma subtypes

Northcott, P. A., Buchhalter, I., Morrissy, A. S., Hovestadt, V., Weischenfeldt, J., Ehrenberger, T., Gröbner, S., Segura-Wang, M., Zichner, T., Rudneva, V. A., et al. (2017) · Nature

Glioma Diagnosis and TreatmentCancer Genomics and Diagnostics

Cited by 1,112

Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target

Horvath, S., Zhang, B., Carlson, M., Lu, K. V., Zhu, S., Felciano, R. M., Laurance, M. F., Zhao, W., Qi, S., Chen, Z., et al. (2006) · Proceedings of the National Academy of Sciences

Glioma Diagnosis and TreatmentBioinformatics and Genomic Networks

Cited by 641

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2010) · Nature

Cancer, Hypoxia, and MetabolismMetabolism and Genetic Disorders

Cited by 613

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma

Cloughesy, T. F., Yoshimoto, K., Nghiemphu, P., Brown, K., Dang, J., Zhu, S., Hsueh, T., Chen, Y., Wang, W., Youngkin, D., et al. (2008) · PLoS Medicine

Glioma Diagnosis and TreatmentPI3K/AKT/mTOR signaling in cancer

Cited by 593

Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy

Pope, W. B., Prins, R. M., Albert Thomas, M., Nagarajan, R., Yen, K. E., Bittinger, M. A., Salamon, N., Chou, A. P., Yong, W. H., Soto, H., et al. (2012) · Journal of Neuro-Oncology

Glioma Diagnosis and TreatmentAdvanced MRI Techniques and Applications

Cited by 318

Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma

Antonios, J. P., Soto, H., Everson, R. G., Moughon, D., Orpilla, J. R., Shin, N. P., Sedighim, S., Treger, J., Odesa, S., Tucker, A., et al. (2017) · Neuro-Oncology

Cancer Immunotherapy and BiomarkersGlioma Diagnosis and Treatment

Cited by 206

TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma

Remke, M., Ramaswamy, V., Peacock, J., Shih, D. J. H., Koelsche, C., Northcott, P. A., Hill, N., Cavalli, F. M. G., Kool, M., Wang, X., et al. (2013) · Acta Neuropathologica

Glioma Diagnosis and TreatmentCancer Genomics and Diagnostics

Cited by 164